THRD — Third Harmonic Bio Share Price
0.000.00%
Last trade - 00:00- $233.21m
- -$51.85m
- 34
- 38
- 26
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.82 | ||
| Price to Tang. Book | 0.82 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -20.48% | ||
| Return on Equity | -16.41% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Its lead product candidate, THB335, is a titratable, oral, small molecule inhibitor. Dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of mast cell driven inflammatory disorders, including urticaria, asthma and gastrointestinal disorders, among others. THB335 maintains the nonclinical pharmacology and selectivity profile of THB001, with structural modifications that are designed to functionally block the site of reactive metabolite formation to mitigate hepatotoxicity risk.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 25th, 2019
- Public Since
- September 15th, 2022
- No. of Shareholders
- 6
- No. of Employees
- 53
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 45,108,594
- Address
- 1700 Montgomery Street, Suite 210, SAN FRANCISCO, 94111
- Web
- https://thirdharmonicbio.com/
- Phone
- +1 2097272457
- Auditors
- Deloitte & Touche LLP
Upcoming Events for THRD
Third Harmonic Bio Inc Annual Shareholders Meeting
Q2 2025 Third Harmonic Bio Inc Earnings Release
Similar to THRD
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Third Harmonic Bio share price?
As of Today at 23:40 UTC, shares in Third Harmonic Bio are trading at $5.17. This share price information is delayed by 15 minutes.
How has the Third Harmonic Bio share price performed this year?
Shares in Third Harmonic Bio last closed at $5.17 and the price had moved by -55.39% over the past 365 days. In terms of relative price strength the Third Harmonic Bio share price has underperformed the S&P500 Index by -59.78% over the past year.
What are the analyst and broker recommendations for Third Harmonic Bio?
The overall consensus recommendation for Third Harmonic Bio is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Third Harmonic Bio dividend yield?
Third Harmonic Bio does not currently pay a dividend.
Does Third Harmonic Bio pay a dividend?
Third Harmonic Bio does not currently pay a dividend.
When does Third Harmonic Bio next pay dividends?
Third Harmonic Bio does not currently pay a dividend.
How do I buy Third Harmonic Bio shares?
To buy shares in Third Harmonic Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Third Harmonic Bio?
As of the previous close price of $5.17, shares in Third Harmonic Bio had a market capitalisation of $233.21m.
Where are Third Harmonic Bio shares listed?
Here are the trading details for Third Harmonic Bio:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: THRD
What kind of share is Third Harmonic Bio?
Based on an overall assessment of its quality, value and momentum Third Harmonic Bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Third Harmonic Bio share price forecast for 2025?
The analyst consensus target price for shares in Third Harmonic Bio is $4.58. That is 11.41% below the last closing price of $5.17.
Analysts covering Third Harmonic Bio currently have a consensus Earnings Per Share (EPS) forecast of -$0.92 for the next financial year.
Find out moreWhat is the trend in the Third Harmonic Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Third Harmonic Bio. Over the past six months, its share price has underperformed the S&P500 Index by -63.76%.
As of the last closing price of $5.17, shares in Third Harmonic Bio were trading -44.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Third Harmonic Bio PE Ratio?
The Third Harmonic Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.17.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Third Harmonic Bio?
We do not have data on Third Harmonic Bio's directors